Lucid Diagnostics (LUCD) Liabilities and Shareholders Equity (2020 - 2026)

Lucid Diagnostics (LUCD) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $34.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 3.92% year-over-year to $34.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $166.4 million (up 38.41% YoY) and the FY2025 annual result came in at $40.4 million, up 31.68% from the prior year.
• Liabilities and Shareholders Equity eased to $34.1 million in Q1 2026, from $40.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $62.1 million in Q1 2022 to a low of $22.6 million in Q3 2024.
• A 5-year average of $38.2 million and a median of $34.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 1064.21% in 2022, down 44.9% in 2022.
• Tracing LUCD's Liabilities and Shareholders Equity over 5 years: stood at $32.5 million in 2022, then declined by 16.12% to $27.3 million in 2023, then advanced by 12.63% to $30.7 million in 2024, then surged by 31.68% to $40.4 million in 2025, then dropped by 15.74% to $34.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $34.1 million (Q1 2026), $40.4 million (Q4 2025), and $53.2 million (Q3 2025), per Business Quant data.